{
  "id": 8948053,
  "title": "FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data",
  "url": "https://urgent.news/2026/09/21/fda-approves-ataxia-telangiectasia-drug-alkermes-reports-adhd-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-21T15:30:28.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/fda-approves-ataxia-telangiectasia-drug-alkermes-reports-adhd-data/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The US FDA has approved a treatment for ataxia-telangiectasia, a rare genetic disease. According to Endpoints News, the treatment, Aqneursa, is from privately held biotech IntraBio.\n\nNo further details on the treatment or the company were provided in the reports.\n\nIn separate news, Novo Nordisk outlined plans to expand its pipeline and find new products, aiming to launch at least five multi-blockbusters by 2030, as reported by STAT News. The company's CEO, Mike Doustdar, presented a strategy to invest more in disease areas outside diabetes and obesity and to be more active in business development.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "STAT News",
        "title": "STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial",
        "url": "https://urgent.news/2026/09/21/stat-alkermes-orexin-agonist-shows-potential-to-treat-adhd-in-early",
        "published": "2026-09-21T11:00:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}